Last reviewed · How we verify
Natrecor (nesiritide)
Nesiritide is a recombinant B-type natriuretic peptide that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and increase sodium excretion.
Nesiritide is a recombinant B-type natriuretic peptide that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and increase sodium excretion. Used for Acute decompensated heart failure with dyspnea at rest or with minimal exertion.
At a glance
| Generic name | Natrecor (nesiritide) |
|---|---|
| Sponsor | Scios, Inc. |
| Drug class | Natriuretic peptide |
| Target | Natriuretic peptide receptor-A (NPR-A) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Nesiritide mimics the action of endogenous B-type natriuretic peptide (BNP), a hormone released by the heart in response to increased wall stress. By activating natriuretic peptide receptor-A (NPR-A) on vascular smooth muscle and endothelial cells, it causes vasodilation and reduces systemic vascular resistance. This decreases both preload and afterload on the failing heart, improving hemodynamics and reducing dyspnea in acute decompensated heart failure.
Approved indications
- Acute decompensated heart failure with dyspnea at rest or with minimal exertion
Common side effects
- Hypotension
- Headache
- Back pain
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
- A Study of Ponsegromab in People With Heart Failure (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Prospective Evaluation of AI-ECG for SHD Detection
- Boston Medical Center Ultrasound Decongestion Study in Heart Failure (NA)
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (PHASE3)
- Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
- Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure (NA)
- REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natrecor (nesiritide) CI brief — competitive landscape report
- Natrecor (nesiritide) updates RSS · CI watch RSS
- Scios, Inc. portfolio CI